Insider · CIK 0001895952
Matthew L. Kaplan
Files at NVCT (Nuvectis Pharma, Inc.). First filing Nov 6, 2025, latest Nov 6, 2025.
In brief
Matthew L. Kaplan files SEC Form 4 as director at NVCT (Nuvectis Pharma, Inc.). Since Nov 6, 2025, Matthew L. Kaplan has reported 1 open-market buy worth $64k and 0 open-market sells worth $0, the latest filed on Nov 6, 2025.
A track record needs three past buys with six months of prices behind them; Matthew L. Kaplan has 0, so none is measured yet.
The newest scored trade: bought $64k of NVCT on Nov 5, 2025, filed Nov 6, 2025, scored 49 (moderate). In the last 12 months: 1 buy worth $64k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NVCT: Nuvectis Pharma, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 49Moderate | Nuvectis Pharma, Inc. | $64k 11,000 shares | +10% | +25% from low-49% from high |
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2026 | NVCT Nuvectis Pharma, Inc. | AGrant or award Common Stock | +35,000 | $0.00 | $0 | 159,760 | Jun 12, 2026 |
| Nov 5, 2025 | NVCT Nuvectis Pharma, Inc. | POpen-market purchase Common Stock | +11,000 | $5.84 | $64k | 124,760 | Nov 6, 2025 |
| Jun 12, 2025 | NVCT Nuvectis Pharma, Inc. | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 113,760 | Jun 12, 2025 |
Questions about Matthew L. Kaplan
Answered from the filings on this page, as of the latest one.
Is Matthew L. Kaplan buying or selling?
In the last 12 months Matthew L. Kaplan reported 1 open-market buy worth $64k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $64k of NVCT on Nov 5, 2025. Grants, option exercises and tax withholding are not counted.
How did Matthew L. Kaplan's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Matthew L. Kaplan has 0.
Where does Matthew L. Kaplan file Form 4?
Matthew L. Kaplan has filed Form 4 at NVCT (Nuvectis Pharma, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.